Startseite Kongressberichte & Archiv BCC2019 Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:

Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients: Accurate Risk Measurement and Local Testing with Prosigna®

• Prognostic performance in different clinical risk groups

• Comparison among currently available multigene signatures

• Prosigna real-world evidence and data

• Value of intrinsic subtyping in clinical practice

SPEAKERS

Dr. Eva Ciruelos: Hospital Universitario 72 de Octubre (Spain):

  Moving to precision medicine: Clinical utility of molecular subtype in breast cancer. 

Professor Bent Ejlertsen, Medical Leader Danish Breast Cancer Cooperative Group,

  Copenhagen University Hospital (Denmark):

  Prosigna real-world evidence and data adjuvant DBCG trials

Dr. Andreas Makris Mount Vernon Cancer Centre (UK):

 Prosigna in the UK, NICE recommendation, OPTIMA Trial.

DISCUSSION